The SmartCella family:
Delivery device
Developing and manufacturing a first-in-class endovascular delivery device, the FDA-approved Extroducer, that enables direct tissue/organ infusions to hard-to-reach organs and tumors.
Cell therapy
Advanced capabilities within stem cell therapy development and inhouse cGMP manufacturing. Globally licensed cardiac stem cell therapy in clinical stages (collaboration with AstraZeneca) and a growing pipeline of stem cell therapies.
Gene therapy and cell-mediated delivery
Creating novel mRNA therapies and platforms that enable cell-mediated delivery of protein and mRNA to specific regions, even within organs or microenvironments.
SmartCella is privately owned and funded
Founded in 2014 and headquartered in Stockholm, Sweden
